JP2018513141A - ヒトカドヘリン−１７、ヒトカドヘリン−５、ヒトカドヘリン−６およびヒトカドヘリン−２０のｒｇｄモチーフに特異的に結合する薬剤 - Google Patents

ヒトカドヘリン−１７、ヒトカドヘリン−５、ヒトカドヘリン−６およびヒトカドヘリン−２０のｒｇｄモチーフに特異的に結合する薬剤 Download PDF

Info

Publication number
JP2018513141A
JP2018513141A JP2017551169A JP2017551169A JP2018513141A JP 2018513141 A JP2018513141 A JP 2018513141A JP 2017551169 A JP2017551169 A JP 2017551169A JP 2017551169 A JP2017551169 A JP 2017551169A JP 2018513141 A JP2018513141 A JP 2018513141A
Authority
JP
Japan
Prior art keywords
seq
cdh17
human
cdr
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017551169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513141A5 (OSRAM
Inventor
アルバレス、ホセ イグナシオ カサル
アルバレス、ホセ イグナシオ カサル
コンデ、ルベン アルバロ バルトロメ
コンデ、ルベン アルバロ バルトロメ
Original Assignee
コンセジョ スペリオール デ インベスティガショネス シエンティフィカス
コンセジョ スペリオール デ インベスティガショネス シエンティフィカス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンセジョ スペリオール デ インベスティガショネス シエンティフィカス, コンセジョ スペリオール デ インベスティガショネス シエンティフィカス filed Critical コンセジョ スペリオール デ インベスティガショネス シエンティフィカス
Publication of JP2018513141A publication Critical patent/JP2018513141A/ja
Publication of JP2018513141A5 publication Critical patent/JP2018513141A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017551169A 2015-04-20 2015-04-20 ヒトカドヘリン−１７、ヒトカドヘリン−５、ヒトカドヘリン−６およびヒトカドヘリン−２０のｒｇｄモチーフに特異的に結合する薬剤 Pending JP2018513141A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2015/058527 WO2016169581A1 (en) 2015-04-20 2015-04-20 Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 rgd motif

Publications (2)

Publication Number Publication Date
JP2018513141A true JP2018513141A (ja) 2018-05-24
JP2018513141A5 JP2018513141A5 (OSRAM) 2018-07-05

Family

ID=52875715

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017551169A Pending JP2018513141A (ja) 2015-04-20 2015-04-20 ヒトカドヘリン−１７、ヒトカドヘリン−５、ヒトカドヘリン−６およびヒトカドヘリン−２０のｒｇｄモチーフに特異的に結合する薬剤

Country Status (6)

Country Link
US (1) US10829560B2 (OSRAM)
EP (1) EP3286218B1 (OSRAM)
JP (1) JP2018513141A (OSRAM)
AU (1) AU2015392603B2 (OSRAM)
ES (1) ES2939013T3 (OSRAM)
WO (1) WO2016169581A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020130053A (ja) * 2019-02-20 2020-08-31 日本電信電話株式会社 細胞接着基板及びその製造方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2703949C1 (ru) * 2018-04-27 2019-10-22 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Вариабельные домены лёгкой и тяжёлой цепи мышиного моноклонального антитела против кадгерина-17 человека, антигенсвязывающий фрагмент (Fab) против кадгерина-17 человека, содержащий указанные домены
US20210116456A1 (en) * 2018-05-16 2021-04-22 Arbele Limited Compositions and methods for diagnosis and treatment of cancer
CN111349157B (zh) * 2018-12-21 2023-06-23 艾比玛特医药科技（上海）有限公司 钙粘附蛋白6的单克隆抗体及其应用
CA3239715A1 (en) * 2021-12-10 2023-06-15 Xun Meng Anti-cdh6 antibodies and antibody-drug conjugates thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003038096A1 (fr) * 2001-10-30 2003-05-08 Shunichiro Kubota Recepteur pour inhibiteur de l'angiogenese et procede de criblage dudit inhibiteur
JP2007537197A (ja) * 2004-05-11 2007-12-20 ガニュメート・ファーマシューティカルズ・アクチェンゲゼルシャフト 腫瘍の診断と治療を目的とした表面会合抗原の同定
JP2009523006A (ja) * 2004-05-07 2009-06-18 アプレラ コーポレイション 脈管疾患に関連する遺伝的多型、その検出方法および使用
JP2012523848A (ja) * 2009-04-20 2012-10-11 オックスフォード ビオトヘラペウトイクス エルティーディー． カドヘリン−１７に特異的な抗体
JP2013505702A (ja) * 2009-09-24 2013-02-21 株式会社ジーンテクノサイエンス 細胞外マトリックスタンパク質のアミノ酸配列ｒｇｄに特異的なヒト化抗体およびそれらの使用
WO2014160499A2 (en) * 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
JP2014530019A (ja) * 2011-10-10 2014-11-17 メディシナルバイオコンバージェンス リサーチ センター グリシルｔＲＮＡ合成酵素及びカドヘリンを利用した癌予防又は治療剤のスクリーニン方法（ｍｅｔｈｏｄｆｏｒｓｃｒｅｅｎｉｎｇａｎａｇｅｎｔｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｃａｎｃｅｒｕｓｉｎｇｇｌｙｃｙｌ−ｔＲＮＡｙｎｔｈｅｔａｓｅａｎｄｃａｄｈｅｒｉｎ）

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003038096A1 (fr) * 2001-10-30 2003-05-08 Shunichiro Kubota Recepteur pour inhibiteur de l'angiogenese et procede de criblage dudit inhibiteur
JP2009523006A (ja) * 2004-05-07 2009-06-18 アプレラ コーポレイション 脈管疾患に関連する遺伝的多型、その検出方法および使用
JP2007537197A (ja) * 2004-05-11 2007-12-20 ガニュメート・ファーマシューティカルズ・アクチェンゲゼルシャフト 腫瘍の診断と治療を目的とした表面会合抗原の同定
JP2012523848A (ja) * 2009-04-20 2012-10-11 オックスフォード ビオトヘラペウトイクス エルティーディー． カドヘリン−１７に特異的な抗体
JP2013505702A (ja) * 2009-09-24 2013-02-21 株式会社ジーンテクノサイエンス 細胞外マトリックスタンパク質のアミノ酸配列ｒｇｄに特異的なヒト化抗体およびそれらの使用
JP2014530019A (ja) * 2011-10-10 2014-11-17 メディシナルバイオコンバージェンス リサーチ センター グリシルｔＲＮＡ合成酵素及びカドヘリンを利用した癌予防又は治療剤のスクリーニン方法（ｍｅｔｈｏｄｆｏｒｓｃｒｅｅｎｉｎｇａｎａｇｅｎｔｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｃａｎｃｅｒｕｓｉｎｇｇｌｙｃｙｌ−ｔＲＮＡｙｎｔｈｅｔａｓｅａｎｄｃａｄｈｅｒｉｎ）
WO2014160499A2 (en) * 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ONCOGENE, vol. 33, JPN6019002770, 2014, pages 1658 - 1669, ISSN: 0004180701 *
PLOS ONE, vol. 8, no. 9, JPN6019002765, 2013, pages 72386, ISSN: 0004180698 *
PLOS ONE, vol. 9, no. 1, JPN6019002772, 2014, pages 85296, ISSN: 0004180702 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, JPN6019002768, 1995, pages 17594 - 17601, ISSN: 0004180700 *
THE JOURNAL OF CELL BIOLOGY, vol. 125, JPN6019002766, 1994, pages 1353 - 1369, ISSN: 0004180699 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020130053A (ja) * 2019-02-20 2020-08-31 日本電信電話株式会社 細胞接着基板及びその製造方法
JP7249579B2 (ja) 2019-02-20 2023-03-31 日本電信電話株式会社 細胞接着基板及びその製造方法

Also Published As

Publication number Publication date
AU2015392603A1 (en) 2017-10-12
AU2015392603B2 (en) 2022-06-02
ES2939013T3 (es) 2023-04-18
EP3286218A1 (en) 2018-02-28
US10829560B2 (en) 2020-11-10
WO2016169581A1 (en) 2016-10-27
CA2980495A1 (en) 2016-10-27
EP3286218B1 (en) 2022-11-30
US20190048090A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
JP6120833B2 (ja) 抗Ａｘｌ抗体及びその使用
BR112020025502A2 (pt) Anticorpos il-11ra
JP2014522638A (ja) 抗Ａｘｌ抗体及びその使用
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
CN109988240B (zh) 抗gpc-3抗体及其用途
CN110088137A (zh) 针对mica和micb蛋白的抗体
JP6280040B2 (ja) ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＤｌｋ−１抗体
WO2018217688A1 (en) Compositions and methods for inhibition of mica/b shedding
US10829560B2 (en) Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 RGD motif
JP2016000713A (ja) 線維芽細胞増殖因子４に対するハイブリドーマクローンおよびモノクローナル抗体
JP6491633B2 (ja) 抗ヒトｃｌｃｐ１抗体とその用途
JP6159010B2 (ja) テトラスパニン８に対するハイブリドーマクローンおよびモノクローナル抗体
CN104837867B (zh) 特异性结合tm4sf5蛋白的新型单克隆抗体及其应用
KR20250067121A (ko) Cnx 항원-결합 분자
JP6159011B2 (ja) Ｃｄ９に対するハイブリドーマクローンおよびモノクローナル抗体
KR20130135869A (ko) 항 단쇄 제4형 콜라겐 폴리펩타이드 항체 및 이를 포함하는 종양의 진단, 예방 또는 치료용 약제
US20240101663A1 (en) Method for inhibiting tumour cell growth based on ccdc112
CA2980495C (en) Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 rgd motif
JP2013013327A (ja) Ｍａｎｓｃ１蛋白質に結合し、抗癌活性を有する抗体
JP2016005449A (ja) Ｃｄ９に対するハイブリドーマクローンおよびモノクローナル抗体
HK40005045B (zh) 用於治疗ror1癌症并抑制转移的抗体和疫苗
HK1178910B (en) Humanized anti cxcr4 antibodies for the treatment of cancer
HK1178910A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20171117

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20171117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201013